Xbiome Showcases Microbiome Anti-Aging Breakthroughs with Academicians, Recognized as an ESG-Driven New Quality Productive Forces Innovation Case Ahead of IPO Filing

Recently, the IFHST International Forum on Health Technology in the Guangdong-Hong Kong-Macao Greater Bay Area and the 2025 Shenzhen Health Industry Annual Conference were held at the Shenzhen Campus of Sun Yat-sen University. The conference focused on in-depth discussions about cutting-edge research and translational applications in microbiota, featuring a keynote speech by Wu Qingping, an academician of the Chinese Academy of Engineering.As a leading enterprise in China's microecology research and industry, Xbiome presented alongside academicians to report the company’s latest scientific advancements in the field of anti-aging through gut microbiota derived from the Chinese population. During the release ceremony of innovative practice cases for new productive forces in Shenzhen's health industry, Xbiome was awarded two outstanding practice case honors: "Social Responsibility Health ESG" and "Technological Innovation."

As an important engine driving innovation in the large health industry, microbiome science is becoming a key force in activating new productive forces and reshaping the industrial landscape. This conference focuses on microbiome to promote the deep integration of technological innovation and the large health industry. In his keynote speech, Academician Wu Qingping shared cutting-edge research achievements in the field of functional microorganisms with the audience. He emphasized that microorganisms are closely related to human health and play a significant role in regulating gut flora and balancing nutrition.

Dr. Tan Yan, Co-founder and CEO of Xbiome, then took the stage to share the latest research progress on anti-aging using gut microbiota derived from the Chinese population. Dr. Tan Yan pointed out that Fecal Microbiota Transplantation (FMT) can effectively regulate NAD⁺ metabolism, estrogen levels, and intestinal barrier function, improving chronic inflammation and cellular energy homeostasis.Xbiome Infuses Cutting-Edge Science into the Health Industry, Discovers NAD⁺ Super Donor, Builds Multi-Level FMT Product Matrix, Promotes Advanced Microecological Technology for the Public, and Addresses Major Health Needs Such as Fat Reduction, Weight Loss, and Aging Delay.

Dr. Tan Yan also brought significant breakthroughs by Xbiome in the field of functional strain anti-aging – the discovery of the Chinese-origin "longevity strain" XA-02D.XA-02D was isolated from the gut of a 96-year-old female centenarian in Meizhou, China. According to patent application documents, this strain can effectively protect ovarian structure, regulate endocrine function, promote endogenous NAD⁺ production, and scientifically delay aging.Currently, the patent application for the XA-02D strain is undergoing accelerated approval, and the clinical research at the drug level in collaboration with Shenzhen Maternity & Child Healthcare Hospital is about to initiate public recruitment. Xbiome will continue to build a deeply integrated AI + BT technology platform to accelerate innovation breakthroughs in microbiome therapeutics and the broader health field.

To showcase Shenzhen's innovative actions and practical achievements in the health industry, set industry benchmarks, the organizing committee has specially launched the "2025 Shenzhen Health Industry New Quality Productivity Innovation Practice Case" selection, demonstrating the practical results and pioneering strength driven by new quality productivity for high-quality development.Xbiome Recognized as an Excellent Practice Case in "Social Responsibility Health ESG" and "Technological Innovation"

Xbiome, with its top-tier scientific team and AI microbiome research and product development platform, conducts cutting-edge scientific research on human gut microbiota and rapidly translates the findings into the development of scientifically evidenced, innovative functional probiotic strains. In recent years, Xbiome has developed several "Chinese-origin strains," such as XA-02D, based on gut microbiota sourced from the Chinese population. With its pharmaceutical-grade technology platform and strong translational capabilities, it has been recognized as a case study in technological innovation.

Moreover, Xbiome, as an AI pharmaceutical company focused on gut microbiota therapy, deeply integrates the ESG concept into the entire process of corporate development, achieving a synergistic win-win of commercial and social value. Over the years, the company's practical achievements in the three dimensions of environment, society, and governance have been fully recognized, and it has been named a model case for social responsibility and health ESG practices.

At this conference, Xbiome set up a special booth at the Sun Yat-sen University Shenzhen Campus venue to introduce its main business, especially the brand-new FMT product portfolio and probiotic products, attracting many experts and industry partners to stop by.Academician Wu Qingping of the Chinese Academy of Engineering, Academician Hao Xiaojiang of the Chinese Academy of SciencesVisit Xbiome's booth, where Xbiome's co-founder and CEO, Dr. Tan Yan, and COO Hao Yi were present to introduce Xbiome's technology platform and industrialization capabilities to the academician. In addition, the Xbiome team also...Dr. Chenzhong Li, Academician of the Canadian Academy of Engineering and the U.S. National Academy of InventorsEngage in in-depth exchanges.

-End-